The new investment marks a significant milestone in offering truly integrated solutions and supply chain advantages for the global pharmaceutical industry. It will allow Bilcare to offer best in class delivery of Aclar® laminates for stability packaging, line trial samples as well as full commercial volumes. Aclar® laminates provide the highest moisture barrier of any films of its type. This investment testifies to Bilcare's commitment to the pharmaceutical sector and the company's fast response to the growing customer demand.
Part of the global Pharmaceutical Packaging Innovation (PPI) Business Unit of Bilcare Research AG, Bilcare Research Inc. offers a variety of mono and barrier blister films to the pharmaceutical packaging industry. In addition to manufacturing pharmaceutical blister films, the company also produces products for other business units of the company.
"This investment in a new laminating line is just the latest component of our continued growth strategy to meet the needs of the rapidly evolving business models of the global pharmaceutical industry. We see increased demand across our entire range of Bilcare Aclar® laminates, from both, ethical and generic pharmaceutical companies," said Kevin Stevens, President and Managing Director of Bilcare Research Inc. "The lamination line is a further execution of Bilcare's strategic investment of €50 Million and is a natural progression to the industry-specific segregation project for our PPI production. The new capacity will be fully available before the end of 2016."
